New PIN1 inhibitors identified through a pharmacophore-driven, hierarchical consensus docking strategy
暂无分享,去创建一个
A. Giordano | V. Canzonieri | T. Tuccinardi | F. Rizzolio | F. Minutolo | M. Macchia | C. Granchi | I. Caligiuri | G. Poli | Matteo Mauceri | Miriana Di Stefano | Joan Arias Estevez | Salvatore Parisi
[1] Colin J. Daniel,et al. Sulfopin is a covalent inhibitor of Pin1 that blocks Myc-driven tumors in vivo , 2021, Nature Chemical Biology.
[2] Flavio Rizzolio,et al. Virtual screening identifies a PIN1 inhibitor with possible antiovarian cancer effects , 2019, Journal of cellular physiology.
[3] A. Giordano,et al. A Guide to PIN1 Function and Mutations Across Cancers , 2019, Front. Pharmacol..
[4] Shiming Yang,et al. Prolyl isomerase Pin1: a promoter of cancer and a target for therapy , 2018, Cell Death & Disease.
[5] V. Canzonieri,et al. Liposomal delivery of a Pin1 inhibitor complexed with cyclodextrins as new therapy for high‐grade serous ovarian cancer , 2018, Journal of controlled release : official journal of the Controlled Release Society.
[6] L. Chiarelli,et al. New Chromane-Based Derivatives as Inhibitors of Mycobacterium tuberculosis Salicylate Synthase (MbtI): Preliminary Biological Evaluation and Molecular Modeling Studies , 2018, Molecules.
[7] Thierry Langer,et al. Conformational Sampling of Small Molecules With iCon: Performance Assessment in Comparison With OMEGA , 2018, Front. Chem..
[8] M. Longhi,et al. Artificial Lipid Membrane Permeability Method for Predicting Intestinal Drug Transport: Probing the Determining Step in the Oral Absorption of Sulfadiazine; Influence of the Formation of Binary and Ternary Complexes with Cyclodextrins , 2018, AAPS PharmSciTech.
[9] A. Rosato,et al. A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action , 2017, Nature Communications.
[10] E. Agostoni,et al. PIN1 Modulates Huntingtin Levels and Aggregate Accumulation: An In vitro Model , 2017, Front. Cell. Neurosci..
[11] Tiziano Tuccinardi,et al. Reliability analysis and optimization of the consensus docking approach for the development of virtual screening studies , 2016, Journal of enzyme inhibition and medicinal chemistry.
[12] Xiao Zhen Zhou,et al. The isomerase PIN1 controls numerous cancer-driving pathways and is a unique drug target , 2016, Nature Reviews Cancer.
[13] T. Hunter,et al. Prolyl isomerase Pin1 in cancer , 2014, Cell Research.
[14] A. Giordano,et al. Pin1 and Nuclear Receptors: A New Language? , 2013, Journal of cellular physiology.
[15] A. Giordano,et al. The Prolyl Isomerase Pin1 Acts Synergistically with CDK2 to Regulate the Basal Activity of Estrogen Receptor α in Breast Cancer , 2013, PloS one.
[16] A. Giordano,et al. Dissecting Pin1 and phospho‐pRb regulation , 2013, Journal of cellular physiology.
[17] A. Giordano,et al. Androgen receptor serine 81 mediates Pin1 interaction and activity , 2012, Cell cycle.
[18] A. Klein-Szanto,et al. Retinoblastoma tumor-suppressor protein phosphorylation and inactivation depend on direct interaction with Pin1 , 2012, Cell Death and Differentiation.
[19] B. Davis,et al. Discovery of cell-active phenyl-imidazole Pin1 inhibitors by structure-guided fragment evolution. , 2011, Bioorganic & medicinal chemistry letters.
[20] B. Davis,et al. Structure-guided design of alpha-amino acid-derived Pin1 inhibitors. , 2009, Bioorganic & medicinal chemistry letters.
[21] Samantha Greasley,et al. Structure-based design of novel human Pin1 inhibitors (I). , 2009, Bioorganic & medicinal chemistry letters.
[22] F. Etzkorn. Pin1 flips Alzheimer's switch. , 2006, ACS chemical biology.
[23] Toshiki Nakai,et al. Prolyl-isomerase Pin1 Accumulates in Lewy Bodies of Parkinson Disease and Facilitates Formation of α-Synuclein Inclusions* , 2006, Journal of Biological Chemistry.
[24] Priti Garg,et al. Modeling breast cancer in vivo and ex vivo reveals an essential role of Pin1 in tumorigenesis , 2004, The EMBO journal.
[25] J. Sowadski,et al. Prevalent overexpression of prolyl isomerase Pin1 in human cancers. , 2004, The American journal of pathology.
[26] Kristina Luthman,et al. Caco-2 monolayers in experimental and theoretical predictions of drug transport1PII of original article: S0169-409X(96)00415-2. The article was originally published in Advanced Drug Delivery Reviews 22 (1996) 67–84.1 , 2001 .
[27] Xiao Zhen Zhou,et al. Function of WW domains as phosphoserine- or phosphothreonine-binding modules. , 1999, Science.
[28] G. Fischer,et al. Selective inactivation of parvulin-like peptidyl-prolyl cis/trans isomerases by juglone. , 1998, Biochemistry.
[29] George W. A. Milne,et al. Graph Theory and Group Contributions in the Estimation of Boiling Points , 1994, J. Chem. Inf. Comput. Sci..
[30] Arup K. Ghose,et al. Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics , 1989, J. Chem. Inf. Comput. Sci..
[31] Thierry Langer,et al. LigandScout: 3-D Pharmacophores Derived from Protein-Bound Ligands and Their Use as Virtual Screening Filters , 2005, J. Chem. Inf. Model..